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ABSTRACT
Chronic myeloid leukemia (CML) is initiated and maintained by the tyrosine kinase BCR-ABL
which activates a number of signal transduction pathways, including PI3K/AKT signaling and
consequently inactivates FOXO transcription factors. ABL-specific tyrosine kinase inhibitors (TKIs)
induce minimal apoptosis in CML progenitor cells, yet exert potent antiproliferative effects,
through as yet poorly understood mechanisms. Here, we demonstrate that in CD341 CML cells,
FOXO1 and 3a are inactivated and relocalized to the cytoplasm by BCR-ABL activity. TKIs caused
a decrease in phosphorylation of FOXOs, leading to their relocalization from cytoplasm (inactive)
to nucleus (active), where they modulated the expression of key FOXO target genes, such as
Cyclin D1, ATM, CDKN1C, and BCL6 and induced G1 arrest. Activation of FOXO1 and 3a and a
decreased expression of their target gene Cyclin D1 were also observed after 6 days of in vivo
treatment with dasatinib in a CML transgenic mouse model. The over-expression of FOXO3a in
CML cells combined with TKIs to reduce proliferation, with similar results seen for inhibitors of
PI3K/AKT/mTOR signaling. While stable expression of an active FOXO3a mutant induced a simi-
lar level of quiescence to TKIs alone, shRNA-mediated knockdown of FOXO3a drove CML cells
into cell cycle and potentiated TKI-induced apoptosis. These data demonstrate that TKI-induced
G1 arrest in CML cells is mediated through inhibition of the PI3K/AKT pathway and reactivation
of FOXOs. This enhanced understanding of TKI activity and induced progenitor cell quiescence
suggests that new therapeutic strategies for CML should focus on manipulation of this signaling
network. STEM CELLS 2014;32:2324–2337
INTRODUCTION
Chronic myeloid leukemia (CML) arises when
the t(9;22) translocation occurs in a normal
hemopoietic stem cell (HSC), generating the
Philadelphia (Ph) chromosome. The resulting
leukemia is driven by the BCR-ABL oncogene,
encoding a constitutively active protein tyro-
sine kinase [1]. First line therapies for CML
involve the protein tyrosine kinase inhibitors
(TKIs) imatinib mesylate, dasatinib, and niloti-
nib. These agents induce rapid cytogenetic
responses (CyR) in the majority of CML
patients in chronic phase (CP) [2], but in most
cases do not eliminate BCR-ABL transcripts,
suggesting persistence of residual disease.
Indeed, residual disease has now been defini-
tively demonstrated in CML patients in CyR [3]
and even in those rare patients who achieve
and maintain a complete molecular response
[4]. These findings, together with the rapid
kinetics of recurrence in most patients who
discontinue TKIs, suggest the presence of leu-
kemic stem/progenitor cells that are TKI-
insensitive [5–8]. The mechanism(s) for TKI-
insensitivity of CML stem/progenitor cells
remain(s) unclear, but may in part be
explained by recent data showing that primi-
tive CML cells do not depend on BCR-ABL
kinase activity for survival [9, 10]. However,
we and others have shown that although CML
stem/progenitor cells are relatively insensitive
to apoptosis induction, TKIs do exert potent,
reversible, antiproliferative effects on these
cells in vitro [4, 6, 11, 12]. Assuming these
effects are replicated within the bone marrow
(BM) microenvironment in patients, then erad-
ication of CML may be made even more diffi-
cult as TKIs may activate cellular pathways in
vivo that lead to G1 arrest and a protective
state of induced quiescence.
BCR-ABL activates multiple signal transduc-
tion pathways involved in cell survival and pro-
liferation, including the Forkhead box,
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CANCER STEM CELLS
subgroup O (FOXO) family of transcription factors (TFs) [13].
In normal stem/progenitor cells, FOXOs localize in the nucleus
and their transcriptional activity results in cell cycle arrest
[14]. Loss of FOXOs results in an aberrant increase in reactive
oxygen species, a dramatic increase in the proportion of
cycling HSCs and eventually in HSC exhaustion [15]. A trans-
duction/transplantation mouse model that reproduces CML-
like myeloproliferative disease has been used to show that
FOXO3a has an essential role in the maintenance of leukemic
stem cells [16]. In this report, the leukemia-initiating cell pop-
ulation contained predominantly active FOXO3a and their abil-
ity to generate the disease was significantly decreased by
deletion of FOXO3a. Furthermore, BCL6 has been identified as
the critical factor mediating the downstream effects of FOXOs
in Ph1 stem cells by repressing transcription of Arf and p53
[17–19]. BCL6 was shown to be repressed in a BCR-ABL-
dependent manner and required for maintenance of CML
stem cells [20, 21]. Induction of FOXO3a in cell lines has been
shown to inhibit cell cycle progression and to induce apopto-
sis through tumor necrosis factor-related apoptosis-inducing
ligand and p53 pathway activation [22, 23]. Cell line studies
suggest that FOXOs may also play a central role in the anti-
proliferative effects of TKIs. In several BCR-ABL-expressing cell
lines, imatinib exposure resulted in FOXO3a activation and cell
cycle arrest [21, 24–26]. However, the role of FOXO TFs on
the antiproliferative effects of TKIs in primary CML has not
been determined.
Here, we have investigated the mechanism through which
TKIs lead to G1 arrest in vitro in primary CD341 CML cells
and in vivo in the SCLtTA/BCR-ABL mouse model of CML [27].
We propose that by understanding the mechanism of TKI-
induced antiproliferative activity, it may be possible to opti-
mize targeting of CML stem/progenitor cells in patients, by
preventing or reversing the induced G1 arrest caused by
FOXO reactivation and forcing these cells into cycle and
toward apoptosis.
MATERIALS AND METHODS
Reagents
Rapamycin and LY294002 were from Calbiochem (Nottingham,
U.K.), imatinib, dasatinib, and nilotinib were from Bristol-
Myers Squibb (Princeton, New Jersey, USA) and Selleckchem
(Newmarket, Suffolk, UK).
Cell Culture
Primary samples were obtained with written informed con-
sent from patients with newly diagnosed CP CML or patients
negative for BM involvement upon lymphoma staging (normal
control stem cells). Samples were enriched for CD341 cells
using CliniMACS and cultured as previously described [28].
TKI Treatment of SCLtTA/BCR-ABL Mice
BM from SCLtTA/BCR-ABL mice (n5 3) was transplanted intrave-
nously into FVBN recipient mice (n5 6). By removing tetracy-
cline from the drinking water, BCR-ABL was induced for 18 days
[27]. Peripheral blood (PB) was analyzed by fluorescence-
activated cell sorting (FACS) after 7 and 15 days of induction to
assess leukemia development. After 18 days, half the mice were
treated by oral gavage for 6 days with 50 mg/kg per day of
dasatinib and the other half with correspondent vehicle. The
mice were euthanized and BM c-Kit1 cells isolated using c-Kit
microbeads and MACS Cell-Separation kit (Miltenyi, Surrey, U.K.).
RNA Extraction and Real-Time Quantitative PCR
An RNA Extraction Kit was used (Qiagen, West Sussex, U.K.)
and cDNA synthesized using a High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems, Warrington, U.K.). Alter-
natively, 300 cells were sorted and processed with “Cells
direct one-step q RT-PCR” (Invitrogen, Paisley, UK). Real-time
quantitative PCR (Q-PCR) was carried out using FAM-MGB
probes for the genes of interest on the ABI7900 (Applied Bio-
systems) and Fluidigm platforms (Fluidigm Corporation, San
Francisco, CA).
Western Blotting
Cell lysates were subject to Western blotting as previously
described [29]. Antibodies used were anti FOXO3a, beta-
Tubulin, Actin, and GAPDH (Cell Signaling, Hitchin, U.K.).
Active Motif Nuclear Extract kit (Rixensart, Belgium) was used
according to the manufacturer’s instructions.
Immuno-fluorescence
CD341, K562, and murine BM c-Kit1 cells were fixed with
3.7% (wt/vol) formaldehyde/PBS and permeabilized in 0.5%
(wt/vol) Triton X-100 for 20 minutes and blocked with 0.2%
(wt/vol) gelatin in PBS. Primary antibodies were applied over-
night and secondary FITC (Sigma-Aldrich Company, Ltd., UK)
antibody for 1 hour at RT. Primary antibodies were anti
FOXO1, FOXO3a, FOXO4, p-FOXO1 (Ser319), and p-FOXO4
(Ser193) (Cell Signaling). Nuclei were stained with 406-
diamidino-2-phenylindole (DAPI) (Vectashield, Burlingame, CA).
Images were analyzed with Confocal Zeiss-Axio Imager M1 flu-
orescence microscope (Carl Zeiss, Jena, Germany). Images
were subject to deconvolution (AxioVision software; Carl Zeiss).
Fluorescence was quantified using AxioVision software. Three-
dimensional fluorescent was measured by Image Processing
and Analysis in Java program. Fluorescence in situ hybridiza-
tion (D-FISH) was performed as previously described [12].
Flow Cytometry
CD341 cells were resuspended in “Fix and Perm” (Merck Chemi-
cals, Ltd., Nottingham, U.K.). Primary antibodies, FOXO1, FOXO3a,
FOXO4, p-FOXO1 (Ser319), p-FOXO3a (Ser253), p-FOXO4
(Ser193), and Cyclin D1 (Cell Signaling), added at RT for 1 hour
and secondary for 30 minutes. Cell cycle was analyzed with PI
(50 mg/ml) (Sigma-Aldrich Company, Ltd., Dorset, UK), DAPI, 7-
AAD, and Ki67 (BD Biosciences, Oxford Science Park, U.K.). Sur-
face markers Annexin V-FITC, CD34-APC, Mac1(CD11b)-PE, and
Gr1-APC (BD Biosciences) were added at RT for 15 minutes.
CD341, K562, and KCL22 Cell Transfections
For transient transfections, pECE-FOXO3aWT or FOXO3aTM
(Addgene, Cambridge, MA) containing wild-type FOXO3a
(FOXO3a WT) or a mutant form insensitive to AKT phosphoryl-
ation (FOXO3a TM) (T32A/S253A/S315A) [30], respectively,
were electroporated into Ph1 K562, KCL22, or primary CD341
cells using the Amaxa Nucleofector Kit V (Lonza, Wolverhamp-
ton, UK) following the manufacturer’s instructions. For stable
transfections, FOXO3a WT and TM were subcloned into
pcDNA 3.1 zeo and transfected into Ph1 K562 cells as above
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and stable cells selected in 200 mg/ml zeocin (Invitrogen).
FOXO3a sh-RNA was subcloned from the pLKO.1 puro vector
(Open Biosystems) into pLKO.1 GFP vector. The same
approach was used to transfect Ph1 K562 with pLKO-GFP-
FOXO3a and pLKO-GFP-scrambled control. After 24 hours, the
cells were sorted based on green fluorescent protein (GFP)
expression using a FACS ARIA Flow Cytometer sorter (Becton
Dickinson).
BrdU Proliferation Assay
Prior to harvesting, cells were labeled with BrdU labeling rea-
gent (Roche Applied Science, West Sussex, UK) for 2 hours.
The cells were then centrifuged and BrdU incorporation was
measured using the Cell Proliferation ELISA (Roche) following
the manufacturer’s instructions.
Gene Expression Profiling Using Microarray
RNA extracted from CD341 cells was analyzed with Affymetrix
U133A microarray chips (GEO accession number GSE52362).
The arrays were performed by Bristol-Myers Squibb (Prince-
ton). Data were RMA normalized and subsequently analyzed
using a paired-sample Rank Product [31]. Significant results
were identified using false discovery rate (FDR)5 0.05. Array
normalized data for FOXOs target genes after in vivo TKI treat-
ment of human CML patients were obtained via NCBI GEO
(accession GSE12211) [32]. Differential expression was identi-
fied by LIMMA using p< .20.
Statistical Analysis
Statistical analyses were performed using the Student’s t test.
A level of *, p .05 was taken to be statistically significant.
Levels of **, p .01 and ***, p .001 were considered highly
statistically significant. Unless otherwise stated, results are
given as mean6 SEM.
RESULTS
BCR-ABL Induces Phosphorylation and Cytoplasmic
Localization of FOXO TFs in Primary CML CD341 Cells
FOXO3a is essential for maintenance of the HSC pool and is
likely the key member of the family in regulating quiescence
[33]. Presently, the precise localization of FOXO in CML pro-
genitor cells is unclear. FOXOs are active in the nucleus, there-
fore to investigate FOXO3a activity, subcellular localization
was performed comparing CP CML and normal progenitor
cells (CD341) (Fig. 1A, left). Immuno-fluorescence (IF) showed
that FOXO3a was localized both in the cytoplasm and in the
nucleus of CML CD341 cells (Fig. 1A, a–d). In contrast,
FOXO3a was predominantly nuclear in normal CD341 cells
(Fig. 1A, e–h). This was confirmed by relative fluorescence
quantification (Fig. 1A, right; ***, p< .001).
To analyze whether BCR-ABL expression has effect on the
transcription of FOXO1, 3a, and 4, Q-PCR was performed in
primary CML and normal CD341 cells. Similar mRNA levels for
FOXO1, 3a, and 4 were detected, indicating that BCR-ABL
does not affect gene expression but regulates FOXOs at the
post-transcriptional level (Fig. 1B).
To determine whether there was a difference in phospho-
rylation of FOXO1, 3a, and 4 between CML and normal
CD341 cells, flow cytometry analysis was performed using
antibodies specific for the phosphorylated forms of these
FOXOs (Fig. 1C, top panel). The geometric mean (GM) value
showed an increase in phosphorylation of FOXO1, 3a, and 4
in CML compared to normal CD341 cells (**, p< .01; ***,
p< .001). No significant difference was detected between
CML and normal samples for total FOXO1, 3a, or 4 (Fig. 1C,
bottom panels).
Dasatinib Induces G1 Arrest, Decreases
Phosphorylation, and Mediates Relocalization of
FOXO1, 3a, and 4 to the Nucleus in Primary CD341
CML Cells
We have previously shown that when CML CD341 cells are
exposed to TKIs in vitro this leads to increased numbers of qui-
escent CD341 CML cells compared to untreated cells [11, 12,
34]. This accumulation of quiescent cells suggests a potent anti-
proliferative activity of TKIs and, if replicated in vivo, would
actually protect CML progenitor cells from the majority of anti-
cancer agents. Dasatinib was selected for these studies as one
of the most potent of the TKIs. The antiproliferative activity of
TKIs against CD341 CML cells was confirmed by cell cycle anal-
ysis, where treatment with 150 nM dasatinib for 24 hours
caused a decrease of cells in S phase (from 33.8% to 28%, *,
p .05) and an increase in G1 phase (from 37.9% to 52.2%, *,
p .05) as shown by representative histogram (Fig. 2A). An
induction of quiescence was shown by staining with Ki67/7-
AAD which demonstrated an increase in Ki67 negative cells
from 11.4% to 47.7% (*, p .05) (Fig. 2B). To examine effects
on phosphorylation of FOXO TFs, CD341 CML cells were
treated with dasatinib for 24 hours and flow cytometry per-
formed. Significant decreases in phosphorylation of FOXO1, 3a,
and 4 in response to dasatinib were observed as indicated by
the relative GM (Fig. 2C, representative histogram in top left
and for n5 4 samples in bar graph, bottom left; *, p .05).
Levels of total FOXO1, 3a, and 4 did not change after dasatinib
treatment (Fig. 2C, representative histograms top right and
n5 3 samples in bar graph, bottom right; *, p> .05).
Since dasatinib decreased the phosphorylation of FOXO1,
3a, and 4, we investigated whether it also caused relocaliza-
tion. CD341 CML cells were treated with 150 nM dasatinib
for 24 hours, at which time IF showed relocalization of total
FOXO1 and 3a from cytoplasm (Fig. 2D, a–f) to nucleus (Fig.
2D, k–p), while little effect was seen with FOXO4. Relocaliza-
tion of FOXO3a being most evident. Although, FOXO1, 3a, and
4 were located in both nucleus and cytoplasm at baseline,
further localization of FOXO1 and 3a to the nucleus was
observed after treatment. The phosphorylated form of FOXO1
also decreased in the cytoplasm after treatment, while little
change was seen with p-FOXO4 (Fig. 2D, g–j and q–t). The
antibody against phospho-FOXO3a was not suitable for IF. Fig-
ure 2D shows representative images and replicate experi-
ments are reported in Supporting Information Figure S1. To
confirm relocalization of total FOXO1 and 3a, the ratio
between cytoplasmic and nuclear fluorescence intensity was
quantified (Fig. 2E; **, p< .01; ***, p< .001). The ratio for
FOXO4 showed no significant difference.
Dasatinib Modulates Expression of Genes that are
Downstream Targets of FOXO TFs
To elucidate the mechanism through which TKIs, and FOXO
reactivation, induce quiescence in primary CML cells, we
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interrogated a microarray dataset carried out for CML CD341
cells treated with 150 nM dasatinib for 16 hours (Fig. 3A).
FOXO1 (ratio5 1.73, p5 6.041 3 1025) and FOXO3a
(ratio5 2.69, p5 2.394 3 10212) were both identified as con-
nected to genes deregulated by dasatinib treatment (by Meta-
Core TF analysis). Normalized data were analyzed using Rank
Products [31] and differentially expressed genes were identi-
fied using a FDR of 0.05. Figure 3A shows genes predicted to
be downstream targets of FOXO TFs (extracted from Meta-
Core KB) which were upregulated (red) or downregulated
(green) following treatment.
To validate these results and examine a possible mecha-
nism by which TKIs regulate quiescence through FOXO TFs,
the changes in gene expression for a selection of key FOXO
target genes (highlighted in black circles) were assayed by Q-
PCR (Fig. 3B; *, p< .05; ***, p< .001). ATM [35] and
CDKN1C/p57 [36] have both been shown to be essential for
maintenance of HSC, while BCL6 has been shown to be
Figure 1. BCR-ABL affects phosphorylation and localization of FOXO isoforms in CML CD341 cells. (A, left): Immuno-fluorescence was
used to show the localization of FOXO3a in CML (a-d) and normal CD341 cells (e–h) (green: FOXO3a; blue: nuclear DAPI; 3100 magnifi-
cation). Three-dimensional images for single cells are shown (d and h). (A, right) This was confirmed by quantification of fluorescence
intensity in cytoplasm versus nucleus (n5 11 and n5 37 cells for CML and normal, respectively). (B): Levels of FOXO1, 3a, and 4 in CML
and normal CD341 cells were measured by Q-PCR (n5 3) as shown by the difference in the Ct values (DCT). (C): Phosphorylation of
FOXO1, 3a, and 4 was measured by flow cytometry in CML and normal CD341 cells (upper panel). Isotype histogram is shown for the
three forms of FOXO since the same secondary anti-Rabbit FITC was used to detect all three antibodies. Bar graphs for three independ-
ent experiments showing ratio of sample over isotype for total (lower panel, Right) and phosphorylated FOXO1, 3a, and 4 (lower panel,
Left) are given (n5 3, ***, p< .001; **, p< .01). Abbreviations: CML, chronic myeloid leukemia; DAPI, 406-diamidino-2-phenylindole;
GM, geometric mean.
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essential for leukemic stem cell (LSC) survival [18]. Following
exposure of CD341 CML cells to TKIs for 24 hours, levels of
ATM, BCL6, and CDKN1C/p57 were modulated in the antici-
pated direction in response to active FOXO TFs and induction
of quiescence, pooled results are shown (Fig. 3B).
We then analyzed the transcriptional regulation of
CCND1/Cyclin D1 (highlighted in Fig. 3A), a known target
of FOXO TFs [14] which is required for cell cycle progres-
sion. After 24 hours dasatinib treatment, the mRNA levels
of CCND1/Cyclin D1 were dramatically decreased (Fig.
3C). Flow cytometric analysis confirmed the decrease in
Cyclin D1 protein although this was more modest (bar
graph and representative histogram; *, p< .05; ***,
p< .001).
TKI Activates FOXO TFs In Vivo
To investigate whether TKI-induced G1 arrest was mediated
by FOXOs in vivo, we initially interrogated a genome wide
Figure 2. FOXO1, 3a, and 4 phosphorylation are affected by TKI treatment in CD341 chronic myeloid leukemia (CML) cells. (A): CD341
CML cells were treated with 150 nM DAS for 24 hours and cell cycle was analyzed by flow cytometry after PI staining (representative
plot, n5 4) (B) Costaining with Ki67/7-AAD was carried out to determine the proportion of quiescent, Ki67-negative cells (representative
plot, n5 3). (C): Levels of pFOXO1, 3a, and 4 (left, lower panel) (n5 4, *, p .05), and total FOXO1, 3a, and 4 (right, lower panel)
(n5 4) following treatment of CD341 CML cells with 150 nM DAS for 24 hours, as measured by flow cytometry. Representative flow
cytometry histograms are shown in the upper panel. (D): CD341 CML cells were either left untreated (a, c, e, g, and i) or treated with
150 nM DAS for 24 hours (k, m, o, q, and s). Localization of FOXO1, 3a, and 4 and of p-FOXO1 and 4 was analyzed by immuno-
fluorescence (overlay image is shown. Green: FOXOs; blue: nuclear DAPI; 3100 magnification). Three-dimensional images of the fluores-
cence intensity are shown (b, d, f, h, j and l, n, p, r, t). (E): Quantification of cytoplasmic versus nuclear fluorescence for total FOXO1,
3a, and 4 (n5 6–27 cells, **, p< .01 and ***, p< .001, respectively). Abbreviations: DAS, dasatinib; NDC, no drug control.
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array profile carried out on samples derived from CP CML
patients treated with imatinib for 7 days (accession
GSE12211) [32]. We observed that several downstream target
genes of FOXOs (in particular of FOXO1 and 4) were regulated
in the same direction as observed in our in vitro analysis
(Supporting Information Figs. S2, S3A). To support these data,
we used a SCLtTA/BCR-ABL inducible mouse model [27]. To
generate mice with a CML-like disease, total BM cells derived
from the transgenic SCLtTA/BCR-ABL mice (n5 3) were pooled
and transplanted into irradiated FVBN recipient mice (Fig. 4A;
n5 6). Omission of tetracycline from the drinking water of
recipient mice led to BCR-ABL expression in the stem/progeni-
tor cells compartment. The mice were checked for signs of
leukemia development after 7 and 15 days by staining with
Gr1 and Mac1 (CD11b) myeloid markers. After 18 days, a sig-
nificant increase Gr1 /Mac1 staining was detected in induced
mice compared to control mice (Fig. 4B, *, p< .05). Half the
cohort was then treated for 6 days with dasatinib (50 mg/kg
per day), while the other half received vehicle only. At the
end of treatment, the mice were sacrificed and analyzed. A
marked decrease in Gr1/Mac1percentage was observed in the
PB of treated mice (Fig. 4C, *, p< .05). BM cells were
enriched for c-Kit1 progenitor cells and phosphorylation of
FOXO TFs analyzed by flow cytometry. Significant decreases in
phosphorylation of FOXO1 and 3a (but not FOXO4) were
observed in the c-Kit1 progenitor cells from dasatinib treated
mice (Fig. 4D, *, p< .05). The antiproliferative activity of TKIs
against c-Kit1 cells was confirmed by cell cycle analysis, where
a significant increase in the percentage of cells in G1 phase
was observed in dasatinib treated mice (Fig. 4E, *, p< .05).
By IF we observed that the dasatinib-mediated decrease
in phosphorylation of FOXO3a was accompanied by a relocali-
zation of FOXO3a to the nucleus in c-Kit1 cells, suggesting its
activation (Fig. 4F). Finally, we analyzed the transcription of
CCND1/Cyclin D1 and found it significantly decreased in the
cells derived from treated mice (Fig. 4G, **, p< .01), suggest-
ing activation of the FOXO3a signaling pathway. Complemen-
tary results were recently observed by Hurtz et al., where
upregulation of FOXO3a target gene BCL6 was detected in a
leukemia mouse model upon TKI treatment [18].
Over-Expression of FOXO3a or Inhibition of PI3K/AKT/
mTOR Signaling Inhibits Proliferation and Enhances
Dasatinib Activity in Ph1 Cells
To determine whether the antiproliferative activity of TKIs
against Ph1 cells was mediated by reactivation of FOXO TFs,
the CML cell line K562 was used to transiently over-express
FOXO3a WT versus a constitutively active mutant form (insen-
sitive to AKT phosphorylation) of FOXO3a (FOXO3a TM). Cells
were transfected with FOXO3a WT, FOXO3a TM, or vector
alone. Cellular fractionation followed by Western blotting
showed that over-expressed FOXO3a mainly localized in the
nuclear fractions, GAPDH being used as a cytoplasmic marker
(Fig. 5A). A BrdU assay performed on these cells showed inhi-
bition of proliferation in cells transfected with FOXO3a, either
WT or TM (Fig. 5B, 12% inhibition with FOXO3a WT and 63%
with FOXO3a TM, **, p< .01, n5 3). The active mutant
FOXO3a TM showed a much higher activity in blocking prolif-
eration of K562 cells compared to FOXO3a WT. Indeed
FOXO3a TM alone inhibited proliferation to a similar degree
Figure 2. (continued)
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as 24 hours incubation with 10 nM dasatinib (used at lower
concentration as these cells are more sensitive than primary
CD341 CML cells), confirming FOXO3a plays an important role
in the cell cycle regulation of these cells. Depending on the
cellular context, high levels of FOXO activity can also induce
apoptosis. As shown in Figure 5C, induced expression of
either FOXO3a WT or TM resulted in modestly enhanced lev-
els of apoptosis (*, p< .05). Similar results were seen when
we transiently transfected these constructs into a second cell
line, KCL22 and CML CD341 cells (Supporting Information Fig.
S3A, S3D). In KCL22 cells, FOXO3a TM induced a significant
increase in the percentage of cells in G1 which was not fur-
ther increased by dasatinib (Supporting Information Fig. S3B;
*, p< .05; **, p< .01). Similarly, the FOXO3a TM induced a
significant increase in apoptosis in these cells, which again
was not enhanced by dasatinib (Supporting Information Fig.
S3C; *, p< .05; **, p< .01). Both the FOXO3a WT and TM
mutants increased the percentage of cells in G1 in the CML
CD341 cells, again this was not further enhanced by dasatinib
in FOXO3a TM-transfected cells (Supporting Information Fig.
S3E). The levels of apoptosis however were only slightly
enhanced by the constructs (Supporting Information Fig. S3F).
In CML, alterations in FOXO activity may not be mediated
solely through the BCR-ABL/PI3K/AKT. We have dissected this
to some degree via treatment with the mTOR inhibitor rapa-
mycin (mTORC2 is an essential AKT activator for FOXO regula-
tion [37]) and the PI3K inhibitor LY294002 to determine
whether these drugs were able to inhibit phosphorylation of
FOXO1, 3a, and 4 and thus restore FOXO activity in CD341
CML cells. The cells were treated for 24 hours with rapamycin
(10 nM), LY294002 (25 mM), dasatinib (150 nM), or the com-
bination of dasatinib with either LY294002 or rapamycin, and
then phosphorylation status of FOXO1, 3a, and 4 was meas-
ured by flow cytometry (Fig. 5D). p values for treatment
Figure 3. Expression of FOXO target genes are altered following TKI treatment. (A): Analysis of an Affymetrix U133A microarray chips
showing downstream targets of FOXO1, 3a, and 4 which were significantly modulated following 16 hours exposure to 150 nM DAS in
CD341 cells. CCN1D/Cyclin D1, BCL6, p57/CDKN1C, and ATM are highlighted. Interactions were taken from MetaCore knowledge base
(22/08/13). (B): CD341 CML cells were treated with TKIs (pool of samples treated with imatinib 5 mM, dasatinib 150 nM, and nilotinib
5 mM) for 24 hours and mRNA levels of ATM, BCL6, and p57/CDKN1C were measured by Q-PCR (three independent samples were ana-
lyzed in triplicate, ***, p< .001; *, p .05). (C): Levels of CCN1D/Cyclin D1 mRNA and protein were analyzed after 24 hours of 150 nM
DAS treatment. A representative flow cytometry histogram is shown for Cyclin D1 protein (n5 3, ***, p< .001; *, p< .05). Abbrevia-
tions: DAS, dasatinib; NDC, no drug control; Q-PCR, quantitative PCR; TKI, tyrosine kinase inhibitor.
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comparisons are reported in Supporting Information Figure
S4. For FOXO1, dasatinib, rapamycin, and LY294002 produced
significant decreases in phosphorylation compared to the no
drug control, but no differences were detected between the
three treatments (*, p> .05). The combination of dasatinib
with rapamycin or LY294002 further decreased FOXO1 phos-
phorylation compared to single agent rapamycin or LY294002,
respectively, suggesting enhanced inhibition by this combina-
tion of inhibitors indicating multiple pathways for activation.
A decrease in phosphorylation of FOXO4 was less evident and
similar for all the drugs used, including the combinations.
Over-Expression of FOXO3a Is Sufficient to Induce
Quiescence in Ph1 Cells
To determine whether over-expression of FOXO3a is sufficient
to induce elevated levels of quiescence in Ph1 cells and could
account for the majority of the antiproliferative activity of TKIs,
K562 cells were transfected to create stable cell lines over-
expressing either FOXO3a WT or FOXO3a TM. By creating stable
cell lines we were able to bypass the apoptotic effects of the
constructs which we saw in transient transfections. Although
the stable cell lines expressed similar levels of total FOXO3a
compared to either parental or vector transduced K562 cells
Figure 4. Dasatinib treatment in SCLtTA/BCR-ABL mice induces FOXO1 and 3a activation in vivo. (A): Experimental layout for the leuke-
mia induction in SCLtTA/BCR-ABL mice and plan of investigation. (B): Percentage of Gr1 and Mac1 in recipient mice after induction of
BCR-ABL expression. (C): Percentage of Gr1 and Mac1 in recipient mice after 6 days of treatment with 50 mg/kg of dasatinib. (D): Level
of phosphorylation of FOXO1, 3a, and 4 in c-Kit1 cells derived from dasatinib and untreated control mice. (E): Cell cycle analysis by PI
staining carried out in c-Kit1 cells derived from dasatinib and untreated control mice. (F): Localization of FOXO3a analyzed by immuno-
fluorescence (overlay image is shown. Green: FOXO3a; blue: nuclear DAPI; 3100 magnification). Three-dimensional images of the fluo-
rescence intensity are shown. (G): mRNA levels of CCN1D/Cyclin D1 were measured by quantitative PCR in c-Kit1 cells derived from
dasatinib and untreated control mice (n5 3/arm) (*, p< .05; **, p< .01). Abbreviations: DAS, dasatinib; DAPI, 406-diamidino-2-
phenylindole; NDC, no drug control.
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(Fig. 6A), both had more nuclear FOXO3a as shown by IF (Fig.
6B). Quantification of nuclear to total fluorescence ratio con-
firmed levels of nuclear FOXO3a were significantly higher in
the WT and TM expressing cells (Fig. 6C, *, p< .05; ***,
p< .001). It is predicted that any cells expressing high levels of
FOXO3a would have exceeded the “apoptosis threshold” and
died during the selection process. To determine the effect of
stable expression of these constructs on cell proliferation, BrdU
Figure 5. Over-expression of FOXO3a induces strong inhibition of proliferation in the K562 cell line. (A): FOXO3a WT, FOXO3a TM (a
constitutively active mutant), and vector control were transiently over-expressed in K562 cells and cytoplasmic versus nuclear fractiona-
tion carried out. Following isolation, 10 mg of nuclear and cytoplasmic lysates were separated by SDS PAGE and the distribution of
FOXO3a determined by Western blotting. GAPDH was used as a cytoplasmic marker. (B): Cells transfected with FOXO3a WT or TM were
treated or not with dasatinib (DAS, 10 nM) for 24 hours and BrdU used to assess proliferation (n5 3, **, p< .01). (C): Levels of apopto-
sis were determined by Annexin V/7-AAD staining (n5 3, *, p .05). (D): CML CD341 cells were treated for 24 hours with rapamycin
(10 nM), LY294002 (25 mM), DAS (150 nM), or the combination of DAS with either LY294002 or rapamycin, and FOXO1, 3a, and 4 phos-
phorylation were measured by flow cytometry (n5 3). Statistical analysis for each treatment is reported in Supporting Information Fig-
ure S2. Abbreviations: DAS, dasatinib; NDC, no drug control.
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Figure 6. Stable transfection of a FOXO3a active mutant into K562 cells increases quiescence. K562 cells were stably transfected with
FOXO3a WT, FOXO3a TM, or an empty vector control. (A): Cells were lysed in RIPA buffer and 20 mg of each were separated by SDS-
PAGE, Western blotting was used to show levels of FOXO3a and Actin. Fold change relative to Actin is shown. (B): Localization of
FOXO3a WT and TM was determined by IF (green: FOXO3a, blue: nuclear DAPI, 3100 magnification) and (C) quantification of nuclear to
total fluorescence (n5 31–45 cells, **, p< .01, *, p .05). (D): BrdU incorporation was used to measure proliferation in stable cell lines
(n5 3, *, p .05), while (E) shows the percentage of Ki67-negative cells as determined by Ki67/7-AAD staining (n5 3, *, p .05). To
compare this to quiescence induced by TKIs, cell lines were treated for 72 hours with IM (1 mM), DAS (10 nM), or NIL (50 nM) before
being stained for Ki67/7-AAD. (F): Shows the number of Ki67-negative cells following treatment (n5 3, **, p< .01; *, p .05 relative to
vector only NDC). (G): Levels of CCND1/Cyclin D1 (left, n5 3 *, p< .001) and p57/CDKN1C (right, n5 3) mRNA were determined by
quantitative PCR. Abbreviations: DAS, dasatinib; DAPI, 406-diamidino-2-phenylindole; IM, imatinib; NDC, no drug control; NIL, nilotinib.
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assay was carried out. As with the transient transfections, the
cells expressing the active mutant FOXO3a TM showed a signifi-
cant decrease in proliferation (Fig. 6D, *, p< .05). Moreover,
over-expression of FOXO3a WT and TM increased the percent-
age of quiescent K562 cells, as shown by Ki67/7-AAD labeling,
with the percentage of quiescent cells higher for FOXO3a TM
versus WT (Fig. 6E, *, p< .05). The two over-expressing cell
lines and vector control were cultured with no drug, imatinib
(1 mM), dasatinib (10 nM), or nilotinib (50 nM) and the abso-
lute number of Ki67-negative cells determined at 72 hours (a
time point chosen to identify cells which were truly quiescent
and not transiently arrested before dying). While treatment of
vector control with each TKI significantly increased the number
of Ki67-negative cells, over-expression of FOXO3a TM alone
was sufficient to induce maximal fourfold increase in quiescent
K562 cells, with no additional increase from the three TKIs (Fig.
6F, *, p< .05; **, p< .01). Although FOXO3a WT significantly
increased the number of quiescent cells by only approximately
Figure 7. FOXO3a knockdown decreases quiescence and increases sensitivity to tyrosine kinase inhibitors (TKIs). (A): K562 cells were
transfected with a FOXO3a shRNA plasmid containing a green fluorescent protein (GFP) tag (sh-FOXO3a) or a scrambled control (sh-
Scramb). Twenty-four hours after transfection, GFP-positive cells were selected and knockdown of FOXO3a was confirmed by quantita-
tive PCR (n5 3, *, p .05). (B): To determine the effect on sensitivity to TKIs, GFP-sorted cells were treated with dasatinib (DAS, 10
nM) for 72 hours and the level of apoptosis measured by Annexin V/DAPI staining (n5 3, *, p .05). (C): Staining with Ki67 and DAPI
was used to determine the number Ki67 negative, quiescent cells following knockdown (left, n5 3, *, p .05). Representative dot-plots
are shown (right). Abbreviations: DAS, dasatinib; DAPI, 406-diamidino-2-phenylindole; NDC, no drug control.
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threefold over vector control, there was no significant further
increase with TKI. These data suggest that the vast majority of
the antiproliferative effects of these agents are likely to sit on
the same pathway as FOXO proteins. We had previously estab-
lished that gene targets of FOXO3a including CCND1/Cyclin D1
and p57/CDKN1C, among others, were modulated upon treat-
ment of CD341 cells with TKIs. To determine whether this was
also the case in our over-expression model, we measured
mRNA expression levels of CCND1/Cyclin D1 and p57/CDKN1C.
The FOXO3a TM cells showed a significant decrease in CCND1/
Cyclin D1 levels (Fig. 5G, Left), although no increase in p57/
CDKN1C (Fig. 6G, right; ***, p< .001; n5 3).
Knockdown of FOXO3a Drives Ph1 Cells into Cycle and
Co-Operates with Dasatinib to Induce Their Apoptosis
Having demonstrated over-expression of FOXO3a is sufficient to
induce quiescence in Ph1 cells we assessed FOXO3a as a
potential therapeutic target. K562 cells were transiently trans-
fected with a GFP containing vector expressing either shRNA
against FOXO3a or scrambled control. After 24 hours, cells
were sorted for GFP expression and treated with and without
10 nM dasatinib for 72 hours. Q-PCR was used to confirm
knockdown in GFP selected cells (Fig. 7A,*, p< .05). Given that
over-expression of active FOXO3a was able to induce quies-
cence, we first wished to address whether in the absence of
TKIs, inhibition of FOXO3a was able to drive cells into cycle.
Ki67 and DAPI staining were used to quantify the number of
quiescent cells in the cultures. Ki67-negative cells were reduced
by 57% following FOXO3a knockdown (Fig. 7B, left; representa-
tive dot plots, right), confirming that inhibition of FOXO signal-
ing was sufficient to drive quiescent cells into cycle (*, p< .05).
To determine how loss of FOXO3a would affect sensitivity of
the cells to TKIs, GFP-selected cells were incubated with and
without 10 nM dasatinib for 72 hours and apoptosis deter-
mined using Annexin V/7-AAD staining. While knockdown alone
did not increase apoptosis, in the presence of TKIs, the per-
centage of late apoptotic cells increased significantly and there
was a trend toward an increase in total apoptosis (*, p< .05;
n5 3) (Fig. 7C). The enhanced apoptosis with dasatinib might
be explained by enhanced cytotoxicity of cells in active cycle.
DISCUSSION
CML is one of the few malignancies in which it has been possi-
ble to identify a plausible targeted therapy. Over the last 15
years, the development of TKIs has improved management for
many CML patients [2]. However, two key issues have been
identified with their use. First, CML stem/progenitor cells are
much less sensitive to apoptosis induction by TKIs as compared
to more mature cells, likely explained by their lack of depend-
ence on BCR-ABL kinase activity for survival [9, 10]. Second,
TKIs exert potent antiproliferative effects against CML stem/
progenitor cells that lead to a state of “induced quiescence.”
This likely protects the cells from genomic instability, known to
be induced by BCR-ABL, and may explain why few patients on
TKIs progress to advanced phase disease. At the same time,
the potential drawback is that quiescence makes the cells far
more difficult to target from a therapeutic point of view.
BCR-ABL signaling activates the PI3K/AKT pathway (among
others) [38], leading to inhibition of FOXO transcriptional activity
[21]. FOXO members play a role at the G0-G1, G1-S, and G2-M
checkpoints via transcriptional modulation of proteins that regu-
late these transitions, thereby inducing cell cycle arrest. Our
study demonstrates that the antiproliferative activity of TKIs
against primary CML CD341 cells is likely mediated by the reac-
tivation of FOXO1, 3a, and 4. Previous reports in cell lines have
shown that imatinib can rescue BCR-ABL-dependent inhibition
of FOXO TFs [21, 22]; however, this is the first report that eluci-
dates the role of FOXO TFs in CML versus normal human hemo-
poietic cells, including CD341 cells. It also mechanistically
demonstrates that FOXO TFs underlie the antiproliferative activ-
ity of TKIs, both in vitro and in an in vivo CML mouse model.
We have shown that in primary CML cells, BCR-ABL regu-
lates FOXO1, 3a, and 4 at the post-transcriptional level, similar
to previous observations [23]. In CML CD341 cells BCR-ABL
expression leads to an increase of FOXO3a in the cytoplasm,
where it is transcriptionally inactive, whereas in normal CD341
cells, FOXO3a is predominantly detected in the nucleus.
Together with FOXO3a, FOXO1 and 4 are also highly phospho-
rylated in CD341 CML cells. Inhibition of BCR-ABL by TKIs
reduces phosphorylation of FOXO TFs, drives their relocalization
to the nucleus, and restores their transcriptional activity. Full
restoration of FOXO activity in primary CML CD341 cells corre-
lated with a dramatic decrease in CCND1/Cyclin D1 mRNA
level, and modulation of key FOXO target genes, ATM, p57/
CDKN1C, and BCL6, which are all required for maintenance of
HSC/LSCs [18, 35, 36]. Similar results were observed in an in
vivo CML model. Here, treatment of the leukemic mice with
dasatinib for 6 days caused activation of FOXO1 and FOXO3a,
as suggested by their phosphorylation status and by a marked
decrease in CCND1/Cyclin D1 mRNA level. In addition, analysis
of the transcriptional profile of CD341 cells derived from CML
patients treated with imatinib showed a regulation of the
canonical FOXO target genes, including p57/CDKN1C and BCL6,
suggesting that activation of FOXOs upon TKI treatment also
occurs in humans in vivo. Although these results are indicative,
a more thorough investigation would be required to definitively
define the role of FOXOs in TKI-mediated G1 arrest in patients.
It has been suggested that upregulation of BCL6 by TKIs is
responsible for the maintenance of CML stem cells through
FOXO3a signaling and by repressing Arf and p53 [18]. These
data, together with our findings, provide evidence that BCL6
and FOXO3a indeed function to protect CML stem cells from
TKI treatment. Interestingly, Naka et al. showed that FOXO3a is
essential for the maintenance of CML stem cells and suggested
that TGF-b-mediated suppression of AKT activity resulted in
increased levels of FOXO activity, positioning the role of TGF-b
directly up-stream of the FOXO/BCL6 axis [16, 19]. Our study
provides further insight into this critical signaling cascade lead-
ing from TGF-b through AKT to FOXO3a/BCL6/p53/ that main-
tains the survival of CML stem cells upon treatment with TKIs.
Although FOXO TFs themselves may not represent straight
forward drug targets, the accumulating evidence suggests that
the signaling network involving BCR ABL/PI3K/AKT/mTOR/
FOXO/BCL6 is critical for the quiescence and survival of CML
stem/progenitor cells and may be targeted for therapy. Naka
et al. has already combined LY364947-mediated TGF-b inhibi-
tion with TKI treatment and found that CML was eradicated
in the CML mouse model [16] and Hurtz et al. inactivated
BCL6 using a retro-inverso BCL6 peptide inhibitor, resulting in
delayed progression of CML when combined with TKIs [18].
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In Ph1 cells, over-expression of WT or the activating
mutant form of FOXO3a, FOXO3a TM, resulted in decreased
proliferation and induction of apoptosis, effects not enhanced
by dasatinib treatment. Furthermore, stable over-expression
of FOXO3a TM increased the percentage of quiescent Ki67-
negative cells to a level that was not further enhanced by
addition of imatinib, dasatinib, or nilotinib. These data suggest
that FOXO reactivation accounts for TKI-induced quiescence in
CML cells. These results with FOXO3a over-expression were
then complemented by results using inhibitors of the BCR-
ABL/PI3K/AKT/mTOR pathway. Inhibition of mTOR signaling by
rapamycin can either activate or inactivate the function of
FOXO TFs in a cell context-dependent fashion [30], whereas
LY294002 is an inhibitor of PI3K. In our hands, these agents
and dasatinib produced very similar levels of inhibition of
phosphorylation of FOXO TFs. Here, we used shRNA against
FOXO3a in combination with TKIs to demonstrate that inhibi-
tion of FOXO signaling drives CML cells into cell cycle allowing
them to undergo apoptosis in response to TKIs.
Finally, we have observed that in the most primitive CML
stem cells (CD341382901 and Lin2CD341382), FOXO TFs are
less inhibited despite the presence of BCR-ABL (Supporting
Information Fig. S5). These data for human CML stem cells
mirror the work of Naka et al. in the CML mouse model [16].
Although we have previously shown that CD341382 CML cells
express high levels of BCR-ABL [12], our current data either
suggest that BCR-ABL is not fully active in this population of
primitive cells or that FOXO activity provides the dominant
signal, thus providing an explanation for their intrinsic quies-
cence. These data suggest that treatment with TKIs of already
quiescent CML stem cells may not have the same effect
observed in progenitor cells. However, targeting the signaling
network required for TKI-induced arrest in progenitor cells
may also have an effect on the primitive TKI-insensitive cells,
assuming a shared mechanism of regulation.
CONCLUSION
Taken together these data confirm that by inhibiting phospho-
rylation of FOXO TFs, TKIs lead to their transcriptional reacti-
vation, providing a valid explanation for the TKI-mediated G1
arrest observed in CML cells. In agreement with these data,
the finding that the FOXO family plays a fundamental role in
normal HSC maintenance makes them excellent candidates to
explain our observations in leukemia [39]. Our data on human
CML cells greatly enhance our understanding of the regulation
of quiescence in CML stem and progenitor cells and provide a
platform from which to aim to manipulate stem cell quies-
cence for therapy.
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